We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Healthpeak Properties
DOC
$13.9B
| $25.3M | 0.06% |
1,290,800
-80,684
| -6% | -$1.54M |
|
352
Skywest
SKYW
$3.73B
| $25.2M | 0.06% |
307,473
-74,979
| -20% | -$5.6M |
|
353
AutoZone
AZO
$46.7B
| $25.1M | 0.06% |
8,476
+286
| +3% | +$837K |
|
354
DoubleVerify
DV
$2.09B
| $25.1M | 0.06% |
1,288,400
-641,700
| -33% | -$15.5M |
|
355
Guardant Health
GH
$23.6B
| $24.9M | 0.06% |
862,100
-44,800
| -5% | -$1.04M |
|
356
Lazard
LAZ
$3.76B
| $24.9M | 0.06% |
651,521
+44,151
| +7% | +$1.72M |
|
357
SLB Ltd
SLB
$80.4B
| $24.8M | 0.06% |
524,921
-164,610
| -24% | -$7.95M |
|
358
SL Green Realty
SLG
$3.67B
| $24.6M | 0.06% |
433,896
+32,985
| +8% | +$1.74M |
|
359
ASML
ASML
$611B
| $24.5M | 0.06% |
24,003
-635
| -3% | -$610K |
|
360
Ingersoll Rand
IR
$27.9B
| $24.5M | 0.06% |
270,183
-20,915
| -7% | -$1.92M |
|
361
Equitable Holdings
EQH
$14.7B
| $24.5M | 0.06% |
600,662
+550,436
| +1,096% | +$21.6M |
|
362
General Mills
GIS
$19.6B
| $24.5M | 0.06% |
387,289
-4,396
| -1% | -$302K |
|
363
CRISPR Therapeutics
CRSP
$5.01B
| $24.2M | 0.06% |
447,606
| – | – |
|
364
Global Payments
GPN
$23.5B
| $24M | 0.06% |
247,918
+37,329
| +18% | +$4.11M |
|
365
Biogen
BIIB
$31.9B
| $23.9M | 0.06% |
102,942
+218
| +0.2% | +$47.4K |
|
366
Valero Energy
VLO
$114B
| $23.8M | 0.06% |
152,048
-13,530
| -8% | -$2.18M |
|
367
Aspen Aerogels
ASPN
$403M
| $23.8M | 0.06% |
998,600
-155,442
| -13% | -$3.65M |
|
368
First Watch Restaurant Group
FWRG
$647M
| $23.8M | 0.06% |
1,354,665
-625,635
| -32% | -$13.1M |
|
369
Hartford Financial Services
HIG
$36.8B
| $23.6M | 0.06% |
234,338
-4,326
| -2% | -$434K |
|
370
Woodward
WWD
$18.9B
| $23.5M | 0.06% |
134,834
+12,612
| +10% | +$2.15M |
|
371
Weatherford International
WFRD
$6.11B
| $23.5M | 0.06% |
191,576
-39,531
| -17% | -$4.72M |
|
372
The Mosaic Company
MOS
$8.09B
| $23.4M | 0.06% |
810,786
-54,659
| -6% | -$1.65M |
|
373
MYR Group
MYRG
$4.22B
| $23.3M | 0.06% |
171,528
-9,494
| -5% | -$1.48M |
|
374
Sprouts Farmers Market
SFM
$6.85B
| $23.2M | 0.05% |
276,856
+44,039
| +19% | +$3.21M |
|
|
RGLS
375
DELISTED
Regulus Therapeutics
RGLS
| $22.9M | 0.05% |
12,852,654
| – | – |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.